Incidence of maxillary osteonecrosis due to the use of bisphosphonates
DOI:
https://doi.org/10.59471/ijhsc2023102Keywords:
Osteonecrosis, Jaw, Oral, Bisphosphonate-InducedAbstract
Introduction: bisphosphonates are products commonly used for the treatment of osteoporosis, mainly for this reason; A wide variety of molecules can be found on the world market. One of the adverse side effects of these drugs is maxillary osteonecrosis reported in patients who have used these products, especially after receiving invasive dental treatments. This is a severe reaction to these drugs and several risk factors have been seen to be involved in its incidence.
Objective: the objective of this work is to find scientific evidence to determine the relationship between the incidence of maxillary osteonecrosis and the use of oral bisphosphonates.
Methods: a systematic search of publications on controlled clinical trials and observational studies reporting incidences of maxillary osteonecrosis in patients using bone antiresorptive agents was carried out in the DialNet, DynaMed, PubMed, MedLine, Nature, JStor, NIH and SciencDirect databases.
Results: t was found that the incidence of maxillary osteonecrosis considerably variable depending on the clinical condition of the patient receiving treatment whit bisphosphonates.
Conclusion: osteonecrosis due to consumption of bisphosphonates is a low frequency pathology, its incidence is directly modified by factors such as polypharmacy and type of underlying pathology, as well as the type of bisphosphonate molecules, dose, and time of exposure to them
References
Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. Journal of Oral and Maxillofacial Surgery [Internet]. 2003 Sep 1 [cited 2022 Apr 19];61(9):1115–7. Available from: http://www.joms.org/article/S0278239103007201/fulltext
Cortés-Motta MC, Fernández-Grisales R. Osteonecrosis de los maxilares: fisiopatología, diagnóstico y tratamiento. CES ODONTOLOGÍA [Internet]. 2016 Nov 1 [cited 2022 Apr 18];29(2):65–77. Available from: https://moz-extension://f32147f0-4560-421d-97ca-2a0483b78f2c/enhanced-reader.html?openApp&pdf=http%3A%2F%2Fwww.scielo.org.co%2Fpdf%2Fceso%2Fv29n2%2Fv29n2a08.pdf
Cardona F, Bagán JV, Sáinz E, Figuerido J, Giner F, Vidán FJ. Osteonecrosis de los maxilares por bisfosfonatos: Actualización y puesta al día [Internet]. 2009 [cited 2022 Apr 17]. Available from: https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1137-66272009000500012
Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Surgery M. Medication-Related Osteonecrosis of the Jaw-2014 Update Special Committee on Medication-Related Osteonecrosis of the Jaws.
Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. Journal of Oral and Maxillofacial Surgery [Internet]. 2004 May 1 [cited 2022 Apr 19];62(5):527–34. Available from: http://www.joms.org/article/S0278239104001958/fulltext
Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. Journal of Clinical Oncology. 2006 Feb 20;24(6):945–52.
Shibahara T, Morikawa T, Yago K, Kishimoto H, Imai Y, Kurita K. National Survey on Bisphosphonate-Related Osteonecrosis of the Jaws in Japan. Journal of Oral Maxillofacial Surgery [Internet]. 2018 [cited 2022 Jun 4];76:2105–12. Available from: https://doi.org/10.1016/j.joms.2018.04.009
Heim N, Götz W, Kramer FJ, Faron A. (No Title). Dentomaxillofacial Radiology. 2019;48.
Kizub D, Schubert MM, Paterson AHG, Clemons M, Dees EC. Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307) HHS Public Access. Available from: http://www.springer.com/gb/open-
Toriumi S, Kobayashi A, Uesawa Y. Comprehensive Study of the Risk Factors for Medication-Related Osteonecrosis of the Jaw Based on the Japanese Adverse Drug Event Report Database. Available from: www.mdpi.com/journal/pharmaceuticals
Rugani P, Walter C, Kirnbauer B, Acham S, Begus-Nahrman Y, Jakse N, et al. dentistry journal Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma. Available from: www.mdpi.com/journal/dentistry
Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. Journal of Clinical Oncology. 2005 Sep 21;23(34):8580–7.
Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ. Incidence of Osteonecrosis of the Jaw in Patients With Multiple Myeloma and Breast or Prostate Cancer on Intravenous Bisphosphonate Therapy. Journal of Oral and Maxillofacial Surgery [Internet]. 2007 Jul 1 [cited 2022 Jun 4];65(7):1328–31. Available from: http://www.joms.org/article/S027823910700328X/fulltext
Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncology. 2008 Sep 1;44(9):857–69.
Thumbigere-Math V, Tu L, Huckabay S, Dudek AZ, Lunos S, Basi DL, et al. A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. American Journal of Clinical Oncology: Cancer Clinical Trials [Internet]. 2012 Aug [cited 2022 Jun 4];35(4):386–92. Available from: https://journals.lww.com/amjclinicaloncology/Fulltext/2012/08000/A_Retrospective_Study_Evaluating_Frequency_and.15.aspx
Corso A, Varettoni M, Zappasodi P, Klersy C, Mangiacavalli S, Pica G, et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 2007 21:7 [Internet]. 2007 Apr 5 [cited 2022 Jun 4];21(7):1545–8. Available from: https://www.nature.com/articles/2404682
Jadu F, Lee L, Pharoah M, Reece D, Wang L. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Annals of Oncology [Internet]. 2007 Dec 1 [cited 2022 Jun 4];18(12):2015–9. Available from: http://www.annalsofoncology.org/article/S0923753419404055/fulltext
Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. The Lancet Oncology. 2014 Aug;15(9):997–1006.
Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Teresa Ambrosini M, et al. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. https://doi.org/101080/10428190802483778 [Internet]. 2009 [cited 2022 Jun 4];49(11):2156–62. Available from: https://www.tandfonline.com/doi/abs/10.1080/10428190802483778
Aguiar Bujanda D, Bohn Sarmiento U, Cabrera Suárez MÁ, Aguiar Morales J. Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Annals of Oncology [Internet]. 2007 Mar 1 [cited 2022 Jun 4];18(3):556–60. Available from: http://www.annalsofoncology.org/article/S0923753419378172/fulltext
Haidar A, Jønler M, Folkmar TB, Lund L. Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw. https://doi.org/103109/00365590903295193 [Internet]. 2009 [cited 2022 Jun 4];43(6):442–4. Available from: https://www.tandfonline.com/doi/abs/10.3109/00365590903295193
Bantis A, Zissimopoulos A, Sountoulides P, Kalaitzis C, Giannakopoulos S, Deftereos S, et al. Bisphosphonate-induced osteonecrosis of the jaw in patients with bone metastatic, hormone-sensitive prostate cancer. Risk factors and prevention strategies. Tumori. 2011 Aug;97(4):479–83.
Sanna G, Preda L, Bruschini R, Cossu Rocca M, Ferretti S, Adamoli L, et al. Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Annals of Oncology [Internet]. 2006 Oct 1 [cited 2022 Jun 4];17(10):1512–6. Available from: http://www.annalsofoncology.org/article/S0923753419473274/fulltext
Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, et al. Combination of Bisphosphonates and Antiangiogenic Factors Induces Osteonecrosis of the Jaw More Frequently than Bisphosphonates Alone. Oncology [Internet]. 2009 Mar [cited 2022 Jun 4];76(3):209–11. Available from: https://www.karger.com/Article/FullText/201931
Ripamonti C, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. 2008;
Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. Journal of Clinical Oncology. 2010 Dec 10;28(35):5132–9.
Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. The Lancet [Internet]. 2011 Mar 5 [cited 2022 Jun 4];377(9768):813–22. Available from: http://www.thelancet.com/article/S0140673610623446/fulltext
Gimsing P, Carlson K, Turesson I, Fayers P, Waage A, Vangsted A, et al. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. The Lancet Oncology [Internet]. 2010 Oct 1 [cited 2022 Jun 4];11(10):973–82. Available from: http://www.thelancet.com/article/S1470204510701984/fulltext
Crawford BS, McNulty RM, Kraut EH, Turowski RC. Extended Use of Intravenous Bisphosphonate Therapy for the Prevention of Skeletal Complications in Patients with Cancer. https://doi.org/103109/07357900902783203 [Internet]. 2009 Nov 13 [cited 2022 Jun 4];27(10):984–8. Available from: https://www.tandfonline.com/doi/abs/10.3109/07357900902783203
Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, Gulley JL, et al. Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Investigation. 2009 Feb;27(2):221–6.
Fehm T, Beck V, Banys M, Lipp HP, Hairass M, Reinert S, et al. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecologic Oncology [Internet]. 2009 Mar 1 [cited 2022 Jun 4];112(3):605–9. Available from: http://www.gynecologiconcology-online.net/article/S0090825808009761/fulltext
Stumpe MR, Chandra RK, Yunus F, Samant S. Incidence and risk factors of bisphosphonate-associated osteonecrosis of the jaws. Head & Neck [Internet]. 2009 Feb 1 [cited 2022 Jun 4];31(2):202–6. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/hed.20941
Then C, Hörauf N, Otto S, Pautke C, von Tresckow E, Röhnisch T, et al. Incidence and Risk Factors of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients Having Undergone Autologous Stem Cell Transplantation. Oncology Research and Treatment [Internet]. 2012 Nov [cited 2022 Jun 4];35(11):658–64. Available from: https://www.karger.com/Article/FullText/343950
Walter C, Al-Nawas B, Bois A du, Buch L, Harter P, Grötz KA. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Cancer. 2009 Apr 15;115(8):1631–7.
ALEXANDRE T A, RALF S, BJÖRN R, EVA W, ALEXANDER G, MARCO B, et al. Incidence of Bisphosphonate-related Osteonecrosis of the Jaw in Consideration of Primary Diseases and Concomitant Therapies. Anticancer Research. 2013 Sep;33(9):3917–24.
Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. British Journal of Haematology [Internet]. 2006 Sep 1 [cited 2022 Jun 4];134(6):620–3. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2141.2006.06230.x
Ortega C, Faggiuolo R, Vormola R, Montemurro F, Nanni D, Goia F, et al. Jaw complications in breast and prostate cancer patients treated with zoledronic acid. http://dx.doi.org/101080/02841860500341173 [Internet]. 2009 Mar [cited 2022 Jun 4];45(2):216–7. Available from: https://www.tandfonline.com/doi/abs/10.1080/02841860500341173
Miyazaki H, Nishimatsu H, Kume H, Suzuki M, Fujimura T, Fukuhara H, et al. Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel. BJU International. 2012 Dec;110(11 B).
Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. Journal of Clinical Oncology. 2009 Nov 10;27(32):5356–62.
Brufsky AM, Sereika SM, Mathew A, Tomifumi O, Singh V, Rosenzweig M. Long-term Treatment with Intravenous Bisphosphonates in Metastatic Breast Cancer: A Retrospective Study. The Breast Journal [Internet]. 2013 Sep 1 [cited 2022 Jun 4];19(5):504–11. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/tbj.12152
Barrett-Lee P, Casbard A, Abraham J, Hood K, Coleman R, Simmonds P, et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: A randomised, open label, non-inferiority phase 3 trial. The Lancet Oncology. 2014 Jan;15(1):114–22.
Rathbone EJ, Brown JE, Marshall HC, Collinson M, Liversedge V, Murden GA, et al. Osteonecrosis of the Jaw and Oral Health–Related Quality of Life After Adjuvant Zoledronic Acid: An Adjuvant Zoledronic Acid to Reduce Recurrence Trial Subprotocol (BIG01/04). Journal of Clinical Oncology. 2013 Jul 20;31(21):2685–91.
Jackson GH, Morgan GJ, Davies FE, Wu P, Gregory WM, Bell SE, et al. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results. British Journal of Haematology. 2014;166(1):109–17.
García Sáenz JA, López Tarruella S, García Paredes B, Rodríguez Lajusticia L, Villalobos L, Díaz Rubio E. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid. Medicina oral, patologia oral y cirugia bucal. 2007;12(5):351–6.
Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk Factors. Journal of Clinical Oncology [Internet]. 2006 Feb 20;24(6):945–52. Available from: https://doi.org/10.1200/JCO.2005.04.2465
Ibrahim T, Barbanti F, Giorgio-Marrano G, Mercatali L, Ronconi S, Vicini C, et al. Osteonecrosis of the Jaw in Patients with Bone Metastases Treated with Bisphosphonates: A Retrospective Study. The Oncologist [Internet]. 2008 Mar 1 [cited 2022 Jun 4];13(3):330–6. Available from: https://academic.oup.com/oncolo/article/13/3/330/6396612
Quispe D, Shi R, Burton G. Osteonecrosis of the Jaw in Patients with Metastatic Breast Cancer: Ethnic and Socio-Economic Aspects. The Breast Journal [Internet]. 2011 Sep 1 [cited 2022 Jun 4];17(5):510–3. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1524-4741.2011.01119.x
Calvo-Villas JM, Tapia Torres M, Govantes Rodríguez J, de Granda EC, Sicilia Guillén F. Osteonecrosis del maxilar en pacientes con mieloma múltiple durante y después del tratamiento con ácido zoledrónico. Medicina Clínica. 2006 Oct;127(15):576–9.
Pavkovic M, Petrushevska G, Jovanovic R, Karanfilski O, Cevreska L, Stankovic S, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphanates. Prilozi. 2010;31(2):39–49.
Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. . Haematologica. 2006;91:968–71.
Cetiner S, Sucak GT, Kahraman SA, Akı SZ, Kocakahyaoglu B, Gultekin SE, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. Journal of Bone and Mineral Metabolism. 2009 Jul 26;27(4):435–43.
Ortega C, Montemurro F, Faggiuolo R, Vormola R, Nanni D, Goia F, et al. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: A retrospective analysis. http://dx.doi.org/101080/02841860601185917 [Internet]. 2009 [cited 2022 Jun 4];46(5):664–8. Available from: https://www.tandfonline.com/doi/abs/10.1080/02841860601185917
Tosi P, Zamagni E, Cangini D, Tacchetti P, di Raimondo F, Catalano L, et al. Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. Blood [Internet]. 2006 Dec 1 [cited 2022 Jun 4];108(12):3951–2. Available from: https://ashpublications.org/blood/article/108/12/3951/22660/Osteonecrosis-of-the-jaws-in-newly-diagnosed
Estilo CL, van Poznak CH, Wiliams T, Bohle GC, Lwin PT, Zhou Q, et al. Osteonecrosis of the Maxilla and Mandible in Patients with Advanced Cancer Treated with Bisphosphonate Therapy. The Oncologist [Internet]. 2008 Aug 1 [cited 2022 Jun 4];13(8):911–20. Available from: https://academic.oup.com/oncolo/article/13/8/911/6397455
Vidal-Real C, Pérez-Sayáns M, Suárez-Peñaranda JM, Gándara-Rey JM, García-García A. Osteonecrosis of the jaws in 194 patients who have undergone intravenous bisphosphonate therapy in Spain. Medicina Oral Patologia Oral y Cirugia Bucal. 2015 May 1;20(3):e267–72.
Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, et al. Prevalence and Risk Factors of Bisphosphonate-Associated Osteonecrosis of the Jaw in Prostate Cancer Patients with Advanced Disease Treated with Zoledronate. European Urology. 2008 Nov 1;54(5):1066–72.
Walter C, Al-Nawas B, Frickhofen N, Gamm H, Beck J, Reinsch L, et al. Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients. Head & Face Medicine. 2010 Dec 8;6(1):11.
Rugani P, Luschin G, Jakse N, Kirnbauer B, Lang U, Acham S. Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer. Clinical Oral Investigations 2013 18:2 [Internet]. 2013 Jun 10 [cited 2022 Jun 4];18(2):401–7. Available from: https://link.springer.com/article/10.1007/s00784-013-1012-5
Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Annals of Oncology. 2008;20:117–20.
Guarneri V, Donati S, Nicolini M, Giovannelli S, Amico RD’, Conte PF. Renal Safety and Efficacy of i.v. Bisphosphonates in Patients with Skeletal Metastases Treated for up to 10 Years; Renal Safety and Efficacy of i.v. Bisphosphonates in Patients with Skeletal Metastases Treated for up to 10 Years. 2005.
Bonomi M, Nortilli R, Molino A, Sava T, Santo A, Caldara A, et al. Renal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: a long-term retrospective analysis. Medical Oncology 2009 27:2 [Internet]. 2009 Mar 28 [cited 2022 Jun 4];27(2):224–9. Available from: https://link.springer.com/article/10.1007/s12032-009-9195-y
Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Annals of Oncology [Internet]. 2013 Feb 1 [cited 2022 Jun 4];24(2):398–405. Available from: http://www.annalsofoncology.org/article/S0923753419368425/fulltext
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Adolfo Ariel Brun, Marcelo Adrián Estrin (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
How to Cite
